Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.58 |
| ▸ | GLO1 | Q04760 | 4/20 | 0.54 |
| ▸ | LTA4H | P09960 | 3/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9007849 | 0.90 | PTGS1 (0.59) | PTGS1GSTK1GLO1LTA4HNOD1 | |
| SCHEMBL19293445 | 0.82 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL5426912 | 0.79 | PTGS1 (0.56) | PTGS1GSTK1GLO1LTA4H | |
| SCHEMBL11874925 | 0.79 | PTGS1 (0.58) | PTGS1GSTK1GLO1LTA4H | |
| SCHEMBL11874912 | 0.79 | PTGS1 (0.58) | PTGS1GSTK1GLO1LTA4H | |
| SCHEMBL19293446 | 0.78 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL19544325 | 0.78 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL9007876 | 0.78 | GLO1 (0.46) | PTGS1GSTK1GLO1LTA4HNOD1 | |
| SCHEMBL12182043 | 0.78 | PTGS1 (0.52) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL4230298 | 0.78 | PTGS1 (0.57) | PTGS1GSTK1GLO1LTA4HNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246148-A1 | Methods and Compositions for Treating Psychotic Disorders | SOUND PHARMACEUTICALS INCORPORATED | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246148-A1 | Methods and Compositions for Treating Psychotic Disorders | GPX4, GPX1, GSR | PTGS1 235/4885GSTK1 14/4885GLO1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.